Author

C. Rheaume

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Brideau-Andersen· 1 shared A. Traversier· 1 shared B. J. Sanstrum· 1 shared B. Jacky· 1 shared B. Lina· 1 shared B. Padey· 1 shared C. Legras-Lachuer· 1 shared C. Nicolas de Lamballerie· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. Brideau-Andersen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using a novel receptor dimerization assay

N. G. James, S. Malik, B. J. Sanstrum, C. Rheaume, R. S. Broide, D. M. Jameson, A. Brideau-Andersen, B. Jacky

This paper develops a receptor dimerization assay to study BoNT/A interactions with FGFRs, showing HC/A induces FGFR dimerization with potency varying by receptor subtype.

Scientific Reports · Apr 9, 2021Peer-reviewedCell Biology

Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures

M. A. Pizzorno, O. Terrier, C. Nicolas de Lamballerie, T. Julien, B. Padey, A. Traversier, M. Roche, M.-E. Hamelin, C. Rheaume, S. Croze, V. Escuret, J. Poissy, B. Lina, C. Legras-Lachuer, J. Textoris, , M. Rosa-Calatrava

This paper identifies 35 FDA-approved drugs with antiviral potential against influenza using transcriptomic signatures, validates 31 in vitro, and highlights diltiazem as a promising candidate for Phase II clinical trials.

bioRxiv · Aug 27, 2018Microbiology